Recent news highlights include AngioDynamics reporting a Q3 loss with revenue growth, increased pro forma adjusted EBITDA, and expansion of its NanoKnife product in Europe for multi-organ tumor ablation.

• AngioDynamics reported a net loss for Q3 but achieved revenue growth driven by Med Tech and Med Device segments [N1].
• The company’s pro forma adjusted EBITDA rose in Q3, accompanied by an upward revision of full-year 2026 guidance [N1].
• AngioDynamics expanded its NanoKnife product offering in Europe targeting multi-organ tumor ablation [N1].

The company demonstrates growth in its Med Tech segment driven by innovative platforms such as Auryon, thrombus management, and NanoKnife, with increasing sales and gross margins. Expansion into international markets and new product introductions support potential for increased sales and profitability. The company's solid liquidity position and ongoing investments in R&D and business development provide a foundation for sustaining growth and operational improvements.

AngioDynamics faces risks from macroeconomic factors including supply chain disruptions, inflationary pressures, tariffs, and labor shortages that may impact manufacturing costs and product availability. The company reported net losses and declining gross margins in some segments, indicating profitability challenges. Competitive pressures, regulatory uncertainties, and potential integration risks from acquisitions also pose challenges to execution and financial performance.

AngioDynamics' moat is supported by its diversified product portfolio targeting cardiovascular and oncology markets, its focus on minimally invasive, image-guided procedures, and its established direct sales force in the U.S. combined with international distributor relationships. The company's investment in R&D and regulatory pathways, along with its clinical and customer engagement capabilities, contribute to competitive differentiation. However, the medical device sector is competitive with risks from technological advances by competitors, regulatory changes, and pricing pressures.

• Macroeconomic and Supply Chain Risks: The company is exposed to risks from inflation, tariffs, labor shortages, supply chain reliability, and raw material availability that may affect manufacturing and costs.
• Profitability and Losses: AngioDynamics reported net losses for recent quarters, with increased losses in the latest quarter, reflecting challenges in managing costs and achieving profitability.
• Competitive and Regulatory Risks: The medical device industry is competitive with risks from technological advances by competitors, regulatory approvals, pricing pressures, and potential litigation.
• Execution Risks: Risks include the ability to successfully develop and launch new products, expand geographically, integrate acquisitions, and manage organizational changes including leadership transitions.

• AngioDynamics Inc is a diversified medical technology company focused on cardiovascular disease and cancer treatment.
• The company designs, manufactures, and sells medical, surgical, and diagnostic devices used by healthcare professionals for vascular access, peripheral vascular disease treatment, oncology, and surgical settings.
• Products are generally used in minimally invasive, image-guided procedures and include disposable or temporarily implanted devices.
• Sales in the U.S. are primarily through a direct sales force; international sales are mainly through distributors.
• End users include interventional radiologists, cardiologists, vascular surgeons, urologists, oncologists, and critical care nurses.
• The company operates two main segments: Med Tech (including Auryon, thrombus management platform, NanoKnife) and Med Device (Core, Venous, Ports, Microwave, Oncology products).
• For the three months ended February 28, 2026, net sales were $78.4 million, an 8.9% increase from the prior year, with Med Tech growing 19.0% and Med Device 1.2%.
• For the nine months ended February 28, 2026, net sales were $233.6 million, a 10.0% increase from the prior year, with Med Tech growing 19.1% and Med Device 3.2%.
• Gross margin for the three months ended February 28, 2026 was 52.9%, down 110 basis points; Med Tech margin was stable at 62.5%, Med Device margin decreased to 44.2%.
• Gross margin for the nine months ended February 28, 2026 was 54.9%, up 50 basis points; Med Tech margin increased to 63.3%, Med Device margin decreased slightly to 47.6%.
• Net loss for the three months ended February 28, 2026 was $8.1 million, or $0.19 loss per share, compared to a $4.4 million loss the prior year.
• Net loss for the nine months ended February 28, 2026 was $25.3 million, or $0.61 loss per share, compared to a $27.9 million loss the prior year.
• Liquidity as of February 28, 2026 included $37.8 million in cash and equivalents, current assets of $155.6 million, current liabilities of $66.1 million, with a current ratio of 2.35 and cash ratio of 0.79.
• The company faces macroeconomic risks including supply chain reliability, labor shortages, inflation, tariffs, and raw material availability.
• AngioDynamics invests in research and development and selective business development to expand product offerings and growth opportunities.
• The company’s execution strategy emphasizes innovative R&D, clinical and regulatory pathway expansion, and customer-centric sales performance.
• Recent news highlights include Q3 loss with revenue growth, increased pro forma adjusted EBITDA, and expansion of NanoKnife in Europe for multi-organ tumor ablation.